Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial

Purpose Breast cancer is the leading cause of cancer mortality in women worldwide. With medical advances, metastatic breast cancer (MBC) patients often live for years with many symptoms that interfere with activities. However, there is a paucity of efficacious interventions to address symptom-related suffering and functional interference. Thus, this study examined the feasibility and preliminary efficacy of telephone-based acceptance and commitment therapy (ACT) for symptom interference with functioning in MBC patients. Methods Symptomatic MBC patients ( N = 47) were randomly assigned to six telephone sessions of ACT or six telephone sessions of education/support. Patients completed measures of symptom interference and measures assessing the severity of pain, fatigue, sleep disturbance, depressive symptoms, and anxiety. Results The eligibility screening rate (64%) and high retention (83% at 8 weeks post-baseline) demonstrated feasibility. When examining within-group change, ACT participants showed decreases in symptom interference (i.e., fatigue interference and sleep-related impairment; Cohen’s d range = − 0.23 to − 0.31) at 8 and 12 weeks post-baseline, whereas education/support participants showed minimal change in these outcomes ( d range = − 0.03 to 0.07). Additionally, at 12 weeks post-baseline, ACT participants showed moderate decreases in fatigue and sleep disturbance (both d s = − 0.43), whereas education/support participants showed small decreases in these outcomes ( d s = − 0.24 and − 0.18 for fatigue and sleep disturbance, respectively). Both the ACT and education/support groups showed reductions in depressive symptoms ( d s = − 0.27 and − 0.28) at 12 weeks post-baseline. Group differences in all outcomes were not statistically significant. Conclusions ACT shows feasibility and promise in improving fatigue and sleep-related outcomes in MBC patients and warrants further investigation.